A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
R Bissonnette, K Papp, C Maari, Y Yao… - Journal of the American …, 2010 - Elsevier
BACKGROUND: Interferon-alfa (IFN-α) has been implicated in the pathogenesis of
psoriasis. OBJECTIVE: To evaluate the safety profile of MEDI-545, a fully human anti–IFN-α
monoclonal antibody and to explore its effect on the involvement of type I IFN-α activity in the
maintenance of established plaque psoriasis. METHODS: We conducted an 18-week,
randomized, double-blind, placebo-controlled, dose-escalating study in 36 subjects with
chronic plaque psoriasis. Subjects received one intravenous dose of MEDI-545 (0.3-30.0 …
psoriasis. OBJECTIVE: To evaluate the safety profile of MEDI-545, a fully human anti–IFN-α
monoclonal antibody and to explore its effect on the involvement of type I IFN-α activity in the
maintenance of established plaque psoriasis. METHODS: We conducted an 18-week,
randomized, double-blind, placebo-controlled, dose-escalating study in 36 subjects with
chronic plaque psoriasis. Subjects received one intravenous dose of MEDI-545 (0.3-30.0 …